- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
RDNT
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
RadNet Inc · Healthcare · Diagnostics & Research
Latest close
63.78 USD
3.6%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is 2.6% above the Trend Line and sits at 37.1% of its 52-week range. The latest completed week returned 3.6%, after a -7.2% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers. Options positioning is bullish with 33/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 5d.
Setup score
33
out of 100
Latest Close
63.78 USD
31 Jul 2026
1W Return
3.6%
latest completed week
4W Return
-7.2%
short-term follow-through
12W Return
9.6%
quarterly tape
Trend Breadth
48.1%
25 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.6%
Latest completed week; four-week move -7.2%.
Indicator stack
26/63
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Bullish
33/100 conviction; expected move 13.4%.
News sentiment
57/100
50 relevant articles in the latest sentiment read.
Event risk
5d
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 2.6% above the Trend Line and sits at 37.1% of its 52-week range. The latest completed week returned 3.6%, after a -7.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2212-week average 0.08
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.22Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -7.2% over four weeks, 9.6% over 12 weeks, and 16.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year25
Trend breadth48.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.72Latest activity-pressure read.
Pressure change1.0%Four-week change in activity pressure.
Leadership-13.96Latest relative-leadership reading.
RS change-25.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 88%
Model confidence 84%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength8/100Blend of value, momentum, and quality. Underlying universe rank 93; rank 1 is best.
Value20/100Relative valuation strength. Underlying universe rank 81; rank 1 is best.
Quality20/100Profitability and accounting quality. Underlying universe rank 81; rank 1 is best.
Momentum31/100Medium-term price momentum. Underlying universe rank 70; rank 1 is best.
Growth75/100Revenue and earnings growth. Underlying universe rank 26; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework4/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 2.3x Market value relative to trailing revenue.
- EV / EBITDA
- 20.3x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 12.9% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 9.4% Gross profit retained from each unit of revenue.
- Operating margin
- 4.8% Operating profit retained from revenue.
- Free-cash-flow margin
- 39.5% Free cash flow generated from revenue.
- Return on invested capital
- 2.7% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 14.7% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 94.1% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 4.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningBullish
RDNT shows bullish options pressure with a 33/100 conviction score, put-call volume ratio of 0.47, expected move of 13.4%, and Sharemaestro trend signal inactive.
Conviction33/100
Expected move13.4%
Put/call volume0.47
Insider activity5 / 6
5 acquisitions and 6 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment57/100
Weighted news tone is neutral across 50 relevant articles.
21 positive · 26 neutral · 3 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings5dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move13.4%Nearest-chain priced movement where available.
52-week drawdown-25.7%Distance below the 52-week high.
13-week volatility6.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher12 of 2614 weeks finished lower.
Best week+13.2%Week of 3 Jul.
Worst week-13.1%Week of 6 Mar.
Latest week+3.6%Week of 31 Jul.
Shape of recent returns
Strong gains4
Modest gains8
Flat weeks0
Modest losses7
Sharp losses7
Recent vol6.6%13-week weekly-return volatility.
Base vol6.9%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew5.8% / -4.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Diagnostics & Research
4-week rank32 / 45
Group average-1.4%
Trend breadth46.7%
Trend46.7%active weekly trend signals
MD80.0%positive activity pressure
RS44.4%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape32/100
Trend, activity pressure, participation, and risk combine to a 32/100 tape read.
Indicator analysis23/100Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 0/12.
Activity pressure 0.22; No reversal markers Factors18/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 59; Small Cap Core rank 83 SVQF4/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 697.0 of 726 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options44/100RDNT shows bullish options pressure with a 33/100 conviction score, put-call volume ratio of 0.47, expected move of 13.4%, and Sharemaestro trend signal inactive.
Bullish · Call-side pressure · Expected move 13.4% Sentiment57/100Weighted news tone is neutral across 50 relevant articles.
What RadNet (RDNT)'s FDA-Cleared AI Breast Ultrasound Rollout Means For Shareholders Insiders5 / 65 acquisitions and 6 disposals in the latest 180-day insider tape.
Earnings5dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 63.78 USD | 3.6% | 62.15 USD | 57.31 USD | 0.72 | -13.96 | 3.4M | Off |
| 24 Jul 2026 | 61.57 USD | -1.0% | 62.39 USD | 57.12 USD | 0.86 | -16.58 | 2.6M | Off |
| 17 Jul 2026 | 62.19 USD | -5.2% | 62.78 USD | 56.93 USD | 1.03 | -17.26 | 3.9M | Off |
| 10 Jul 2026 | 65.60 USD | -4.6% | 63.26 USD | 56.76 USD | 0.92 | -16.55 | 3.7M | Off |
| 3 Jul 2026 | 68.75 USD | 13.2% | 63.54 USD | 56.54 USD | 0.72 | -11.12 | 4.4M | Off |
| 26 Jun 2026 | 60.74 USD | 13.0% | 63.87 USD | 56.29 USD | 0.30 | -20.86 | 6.3M | Off |
| 19 Jun 2026 | 53.74 USD | -5.2% | 64.60 USD | 56.11 USD | -0.19 | -33.35 | 5.7M | Off |
| 12 Jun 2026 | 56.71 USD | 4.4% | 65.58 USD | 55.98 USD | -0.62 | -28.21 | 3.4M | Off |
| 5 Jun 2026 | 54.34 USD | -2.1% | 66.19 USD | 55.82 USD | -0.94 | -29.95 | 4.4M | Off |
| 29 May 2026 | 55.53 USD | 2.1% | 66.99 USD | 55.68 USD | -1.07 | -32.04 | 2.1M | Off |
| 22 May 2026 | 54.40 USD | 3.8% | 67.67 USD | 55.52 USD | -1.24 | -31.92 | 2.2M | Off |
| 15 May 2026 | 52.39 USD | -10.0% | 68.64 USD | 55.35 USD | -1.27 | -34.05 | 7.0M | Off |
| 8 May 2026 | 58.19 USD | 2.4% | 69.46 USD | 55.20 USD | -1.33 | -27.53 | 4.9M | Off |
| 1 May 2026 | 56.85 USD | -1.4% | 69.87 USD | 55.00 USD | -1.51 | -25.72 | 3.8M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.